Important Safety Information
Contraindications: None.
Administration site reactions include pain and swelling.
ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.
Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.
In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.
Ascorbic acid may interfere with laboratory tests based
on oxidation-reduction reactions, including blood and
urine glucose testing, nitrite and bilirubin levels, and
leucocyte count testing. If possible, laboratory tests based
on oxidation-reduction reactions should be delayed until
24 hours after infusion of ASCOR®.
Please see accompanying Full Prescribing Information for ASCOR®.
